Aydin Huseynov
Stock Analyst at Ladenburg Thalmann
(0.66)
# 3,978
Out of 4,964 analysts
55
Total ratings
30.61%
Success rate
-28.01%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Aydin Huseynov
Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
ARDX Ardelyx | Assumes: Buy | $11 | $6.19 | +77.71% | 1 | Mar 7, 2025 | |
URGN UroGen Pharma | Assumes: Buy | $31 | $19.54 | +58.65% | 1 | Feb 19, 2025 | |
MRKR Marker Therapeutics | Maintains: Buy | $11 → $19 | $0.94 | +1,921.49% | 2 | Oct 21, 2024 | |
CRVS Corvus Pharmaceuticals | Maintains: Buy | $12 → $21 | $5.50 | +281.82% | 3 | Sep 16, 2024 | |
CMPX Compass Therapeutics | Upgrades: Buy | $5 | $3.28 | +52.44% | 2 | Sep 16, 2024 | |
ACRV Acrivon Therapeutics | Upgrades: Buy | $16 | $1.37 | +1,067.88% | 3 | Sep 16, 2024 | |
CLDI Calidi Biotherapeutics | Initiates: Buy | $120 | $1.67 | +7,085.63% | 1 | Jun 27, 2024 | |
CAPR Capricor Therapeutics | Maintains: Buy | $24 → $25 | $6.25 | +300.00% | 2 | May 14, 2024 | |
BDRX Biodexa Pharmaceuticals | Initiates: Buy | $2,000 | $5.71 | +34,926.27% | 1 | Feb 8, 2024 | |
PMVP PMV Pharmaceuticals | Initiates: Buy | $7 | $1.43 | +389.51% | 1 | Dec 27, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $2.16 | +362.96% | 1 | Oct 10, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $13.30 | +351.13% | 1 | Sep 22, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $6 | $3.06 | +96.08% | 2 | Aug 14, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $4.98 | +100.80% | 3 | Jun 5, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $375 → $240 | $0.66 | +36,071.82% | 2 | May 16, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $104 → $182 | $10.76 | +1,591.45% | 2 | Apr 28, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Speculative Buy | $180 → $80 | $0.21 | +37,476.33% | 1 | Apr 4, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $3.04 | +557.89% | 1 | Mar 7, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.18 | - | 4 | Nov 4, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.59 | - | 2 | Aug 23, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $2.65 | +126.84% | 1 | Jul 27, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $6.67 | +214.84% | 1 | Jul 13, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10,500 | $7.38 | +142,176.42% | 1 | May 6, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $2.35 | +1,474.47% | 1 | May 2, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $300 | $29.28 | +924.59% | 3 | Nov 8, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $586.96 | - | 6 | Nov 5, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $89 | $84.84 | +4.90% | 2 | Jul 20, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | n/a | $138.13 | - | 1 | Sep 30, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Speculative Buy | $1,000 | $5.95 | +16,706.72% | 1 | Jun 16, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $336 | $2.46 | +13,558.54% | 1 | May 21, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $3.42 | +426.32% | 1 | Mar 19, 2020 |
Ardelyx
Mar 7, 2025
Assumes: Buy
Price Target: $11
Current: $6.19
Upside: +77.71%
UroGen Pharma
Feb 19, 2025
Assumes: Buy
Price Target: $31
Current: $19.54
Upside: +58.65%
Marker Therapeutics
Oct 21, 2024
Maintains: Buy
Price Target: $11 → $19
Current: $0.94
Upside: +1,921.49%
Corvus Pharmaceuticals
Sep 16, 2024
Maintains: Buy
Price Target: $12 → $21
Current: $5.50
Upside: +281.82%
Compass Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $5
Current: $3.28
Upside: +52.44%
Acrivon Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $16
Current: $1.37
Upside: +1,067.88%
Calidi Biotherapeutics
Jun 27, 2024
Initiates: Buy
Price Target: $120
Current: $1.67
Upside: +7,085.63%
Capricor Therapeutics
May 14, 2024
Maintains: Buy
Price Target: $24 → $25
Current: $6.25
Upside: +300.00%
Biodexa Pharmaceuticals
Feb 8, 2024
Initiates: Buy
Price Target: $2,000
Current: $5.71
Upside: +34,926.27%
PMV Pharmaceuticals
Dec 27, 2023
Initiates: Buy
Price Target: $7
Current: $1.43
Upside: +389.51%
Oct 10, 2023
Initiates: Buy
Price Target: $10
Current: $2.16
Upside: +362.96%
Sep 22, 2023
Initiates: Buy
Price Target: $60
Current: $13.30
Upside: +351.13%
Aug 14, 2023
Maintains: Buy
Price Target: $10 → $6
Current: $3.06
Upside: +96.08%
Jun 5, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $4.98
Upside: +100.80%
May 16, 2023
Maintains: Buy
Price Target: $375 → $240
Current: $0.66
Upside: +36,071.82%
Apr 28, 2023
Maintains: Buy
Price Target: $104 → $182
Current: $10.76
Upside: +1,591.45%
Apr 4, 2023
Maintains: Speculative Buy
Price Target: $180 → $80
Current: $0.21
Upside: +37,476.33%
Mar 7, 2023
Initiates: Buy
Price Target: $20
Current: $3.04
Upside: +557.89%
Nov 4, 2022
Downgrades: Neutral
Price Target: n/a
Current: $5.18
Upside: -
Aug 23, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.59
Upside: -
Jul 27, 2022
Initiates: Buy
Price Target: $6
Current: $2.65
Upside: +126.84%
Jul 13, 2022
Initiates: Buy
Price Target: $21
Current: $6.67
Upside: +214.84%
May 6, 2022
Initiates: Buy
Price Target: $10,500
Current: $7.38
Upside: +142,176.42%
May 2, 2022
Initiates: Buy
Price Target: $37
Current: $2.35
Upside: +1,474.47%
Nov 8, 2021
Upgrades: Buy
Price Target: $300
Current: $29.28
Upside: +924.59%
Nov 5, 2021
Downgrades: Hold
Price Target: n/a
Current: $586.96
Upside: -
Jul 20, 2021
Upgrades: Buy
Price Target: $89
Current: $84.84
Upside: +4.90%
Sep 30, 2020
Initiates: Hold
Price Target: n/a
Current: $138.13
Upside: -
Jun 16, 2020
Initiates: Speculative Buy
Price Target: $1,000
Current: $5.95
Upside: +16,706.72%
May 21, 2020
Initiates: Buy
Price Target: $336
Current: $2.46
Upside: +13,558.54%
Mar 19, 2020
Initiates: Buy
Price Target: $18
Current: $3.42
Upside: +426.32%